{name}
{subtitle}
A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)
city
~42 mi. (Jönköping, Sweden, +144 more cities)
facility
Lanssjukhuset Ryhov ( Site 2103)
drug
belzutifan, +3 more drugs
drug type
immunotherapy, +1 more type
Perioperative Pembrolizumab (MK-3475) Plus Neoadjuvant Chemotherapy Versus Perioperative Placebo Plus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle-invasive Bladder Cancer (MIBC) (MK-3475-866/KEYNOTE-866)
city
~42 mi. (Jönköping, Sweden, +159 more cities)
facility
Laenssjukhuset Ryhov ( Site 1205)
drug
cisplatin, +2 more drugs
drug type
chemotherapy, +1 more type
Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053)
city
~76 mi. (Linköping, Sweden, +176 more cities)
facility
Universitetssjukhuset i Linkoping. ( Site 2222)
condition
Endometrial Carcinoma, +1 more condition
drug
chemotherapy, +2 more drugs
drug type
chemotherapy, +2 more types